Natsimbio may become sole supplier of blood-plasma and other drugs to Russian government

24 June 2016

The Russian government has appointed the National immuno-biological company (Natsimbio), the recently established Russian drugmaker which is part of the Russian state and defense corporation Rostec, as sole supplier of blood plasma drugs for the period of 2016-2017 years through the signing of a contract with the company.

That means that Natsimbio will become a single supplier of blood plasma drugs for the needs of Russian hospitals and ambulatory-care clinics, reports The Pharma Letter's local correspondent.

In the meantime, this could be just the beginning, as, in addition to blood plasma drugs, the company may be appointed as a sole supplier of drugs against tuberculosis, HIV and viral hepatitis until 2020, which will mean multi-million contracts for the company with the Russian government.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK